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Founder Mutations of BRCA1 and BRCA2 in North
American Families of Polish Origin That Are Affected
with Breast Cancer
To the Editor:
We have recently identified five founder mutations in a
panel of 66 families with breast/ovarian cancer who were
ascertained in western Poland (Go´rski et al. 2000). Of the
35 families with mutations, 33 had one of the five re-
current BRCA1 mutations, including 18 families with the
5382 insC mutation. Only one BRCA2 mutation was
found in the 66 families.
A significant proportion of North American families
claim Polish ancestry. We were interested to see whether
the same mutations were present in families residing in
North America who claimed Polish ancestry. This infor-
mation might be useful for genetic counseling and to fa-
cilitate mutation detection.
We attempt to record ethnicity for all families affected
by breast cancer listed in our database. From a source of
1,010 families who underwent genetic evaluation, we
identified 23 families of Polish ancestry. All families were
tested for the five Polish founder mutations. We also com-
pleted the protein truncation test (PTT) of exon 11 of
BRCA1 and exons 10 and 11 of BRCA2. A few families
had mutations identified through an earlier study (Serova
et al. 1997).
No BRCA2 mutation was seen in the 23 families, but
10 BRCA1 mutations were found (43%), including 6
5382insC mutations. The other mutations included one
instance each of 964del4, IVS16-581del1014, C1806T,
and 4184del4. None of these were present in the original
panel of Polish families (Go´rski et al. 2000). We identified
four other families in our database who did have one of
the putative Polish founder mutations (other than
5382insC and 185delAG)—but none of these families
were Polish. There were two unrelated Czech families
with the 3819del5 mutation, one Lithuanian family with
the 4153delA mutation, and one family of mixed Euro-
pean ancestry with the T300Gmutation. These three mu-
tations have been reported to the Breast Cancer Infor-
mation Core database 13 times, 7 times, and 46 times,
respectively. Only two of the families reported to BICwere
said to be Polish (both had the 3819del5 mutation). The
4154delA mutation is common in Russia (Gayther et al.
1997). In summary, none of the mutations that are com-
mon in Poland appear to be specific to the population.
Our results support the claim that the majority of
mutation-carrying families with Polish ancestry carry the
BRCA1 5382insC mutation, in Poland and in North
America. We believe that, when resources are limited, it
may be efficient to offer testing for this mutation prior
to undertaking a complete evaluation for Polish families
seeking genetic testing. The low frequency of BRCA2
mutations in Polish families, in Poland and in North
America, remains to be explained.
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Vacuoliting Megalencephalic Leukoencephalopathy
To the Editor:
In a report in the February 2000 issue of the Journal,
Topc¸u et al. (2000) reported on the mapping of vacu-
oliting megalencephalic leukoencephalopathy with sub-
cortical cysts to chromosome 22q, in a 3-cM interval
between the markers D22S1161 and n66c4. The cen-
tromeric boundary was defined by a recombination
event with the marker D22S1161. However, how n66c4
was determined as the telomeric boundary is not clear.
n66c4 reaches its maximal LOD score at . Thevp .00
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highest multipoint LOD score was also reachedwith that
marker, and the haplotypes shown in figure 2 of the
report do not reveal any recombination events with this
marker, either in the patients or in the unaffected sibs.
The interval containing the gene should therefore be de-
fined as being between D22S1161 and the telomere.
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